Routine care of patients with Waldenstrom's disease treated between 2020 and 2021 in hematology practices in Germany

Routine care of patients with Waldenstrom's disease treated between 2020 and 2021 in hematology practices in Germany - Waldenstrom 20/21

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00027642

Enrollment

500

Registered

2022-01-12

Start date

2022-01-18

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C88.0

Interventions

Group 1: non-interventional

retrospective and anonymized treatment data will be collected that were documented in the course of routine care

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Diagnosis Waldenstrom's disease. Treatment / care in the period 2020 - 2021 in a hematology group practice in Germany.

Exclusion criteria

Exclusion criteria: Patients have objected to scientific use of their treatment data

Design outcomes

Primary

Measure	Time frame
Description of routine care reality	—

Secondary

Measure	Time frame
In detail, the following questions will be analyzed: 1. what percentage of all patients requires treatment? 2. what is the time period between diagnosis and therapy? 3. what is the current therapy of Waldenstrom's disease? What is the role of chemoimmunotherapies compared to therapies with a Brutons tyrosine kinase inhibitor? 4. What is the role of supportive therapy, particularly infection prophylaxis, in the treatment of Waldenstrom's disease? 5. Which patient care pathways dominate in the routine care reality?	—

Measure

Time frame

In detail, the following questions will be analyzed: 1. what percentage of all patients requires treatment? 2. what is the time period between diagnosis and therapy? 3. what is the current therapy of Waldenstrom's disease? What is the role of chemoimmunotherapies compared to therapies with a Brutons tyrosine kinase inhibitor? 4. What is the role of supportive therapy, particularly infection prophylaxis, in the treatment of Waldenstrom's disease? 5. Which patient care pathways dominate in the routine care reality?

—

Countries

Germany

Contacts

Public ContactStefan Feiten

Institut für Versorgungsforschung in der Onkologie

s.feiten@invo-koblenz.de0261 / 921 5693-23

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026